---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-253493"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:35:38.165932+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sana cuts workforce 29%, delays SG299 IND; 2024 cash burn under $200M

## Summary
- Workforce reduction of ~29%; expects 2024 operating cash burn below $200 million.
- IND submitted for SC291 (HIP CD19 CAR T) in autoimmune diseases; initial data expected 2024.
- Delaying SG299 (in vivo CAR T) IND; reducing near-term investment in fusogen platform.
- SC262 (HIP CD22 CAR T) IND on track for Q4 2023; proof-of-concept data expected 2024.
- HIP-modified islet cell CTA submitted for type 1 diabetes trial; data expected 2023 and 2024.

## SEC filing metadata
- accession: 0001193125-23-253493
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000119312523253493/0001193125-23-253493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000119312523253493/d526014d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-253493
- JSON: https://secwatch.observer/filing/0001193125-23-253493.json
- Plain text: https://secwatch.observer/filing/0001193125-23-253493.txt

## Key facts
- Restructurings & Charges
  Sana Biotechnology, Inc. announced a restructuring with charges of approximately $5.1 million and $1.7 million affecting fusogen platform for in vivo gene delivery (approximately 29%).
  - Type: restructuring
  - Charge: approximately $5.1 million and $1.7 million
  - Affected area: fusogen platform for in vivo gene delivery
  - Headcount: approximately 29%
  source text: On October 10, 2023, Sana Biotechnology, Inc. (“Sana”) announced a portfolio update to increase its focus on its ex vivo cell therapy product candidates. As part of the portfolio update, Sana plans to reduce its near-term investment in its fusogen platform for in vivo gene delivery, including by delaying the investigational new drug (IND) filing for its SG299 program, and reduce its workforce by approximately 29%. Sana anticipates that the portfolio update and associated reduction in force will be substantially complete by the fourth quarter of 2023, which is expected to result in 2024 operating cash burn of less than $200.0 million. In connection with the portfolio update, Sana anticipates it will incur approximately $5.1 million and $1.7 million of cash-based expenses related to employee severance, benefits and related costs in the fourth quarter of 2023 and the first quarter of 2024, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000119312523253493/0001193125-23-253493-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.